Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia.
- 1 August 1991
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Stroke
- Vol. 22 (8) , 1075-1077
- https://doi.org/10.1161/01.str.22.8.1075
Abstract
Experimental ischemia models have shown the antitussive dextromethorphan to be an N-methyl-D-aspartate antagonist with neuroprotective properties. We treated 10 patients with a history of recent stroke or transient ischemic attack with oral dextromethorphan (60 mg q.i.d.) for 3 weeks in a placebo-controlled, double-blind, crossover tolerance study. We documented no clinical evidence of toxicity attributable to dextromethorphan in this preliminary study.Keywords
This publication has 9 references indexed in Scilit:
- Potential Therapeutic Uses of N-Methyl-D-Aspartate Antagonists in Cerebral IschemiaClinical Neuropharmacology, 1990
- Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related DrugsScience, 1989
- N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia?Annals of Neurology, 1989
- Delayed treatment with dextromethorphan and dextrorphan reduces cerebral damage after transient focal ischemiaNeuroscience Letters, 1988
- Morphinans attenuate cortical neuronal injury induced by glucose deprivation in vitroBrain Research, 1988
- The Estimation of Solubility in Binary Solvents: Application of the Reduced 3-Suffix Solubility Equation to Ethanol–Water MixturesPharmaceutical Research, 1988
- Dextrorphan and dextromethorphan attenuate hypoxic injury in neuronal cultureNeuroscience Letters, 1987
- The Polymorphic Metabolism of DextromethorphanThe Journal of Clinical Pharmacology, 1987
- Glutamate and the pathophysiology of hypoxic–ischemic brain damageAnnals of Neurology, 1986